Abstract 971P
Background
The growing demand for hepatic resection in elderly hepatocellular carcinoma (HCC) patients highlights the need to understand the impact of preoperative frailty on surgical outcomes. This multicenter retrospective cohort study aimed to investigate the association between frailty and short-term and long-term outcomes following hepatic resection in elderly HCC patients.
Methods
We conducted a multicenter retrospective cohort study on elderly patients (≥70 years) who underwent curative-intent hepatic resection for HCC at 10 Chinese hospitals in China from 2012 to 2021. Frailty was assessed using the Clinical Frailty Scale (CFS), with frailty defined as CFS ≥ 5. Primary outcomes included overall survival (OS) and recurrence-free survival (RFS); secondary outcomes encompassed postoperative 30-day morbidity, 30-day mortality, and 90-day mortality. We compared these outcomes between patients with and without preoperative frailty.
Results
Of the 488 elderly patients, 148 (30.3%) were considered frail. Frail patients experienced significantly higher postoperative 30-day morbidity (68.9% vs. 43.2%), 30-day mortality (4.1% vs. 0.6%), and 90-day mortality (6.1% vs. 0.9%) than non-frail patients (all P<0.05). During a median follow-up of 37.7 months (IQR: 20.4-57.8), frail patients demonstrated significantly worse median OS (41.6 months [95% CI, 32.0-51.2] vs. 69.7 months [95% CI, 55.6-83.8]) and RFS (27.6 months [95% CI, 23.1-32.1] vs. 42.7 months [95% CI, 34.6-50.8]) compared to non-frail patients (both P<0.01). Multivariate Cox-regression analysis revealed frailty as a significant predictor for OS (HR 1.61, 95% CI 1.22-2.13, P=0.001) and RFS (HR 1.32, 95% CI 1.03-1.70, P=0.028).
Conclusions
Frailty was significantly associated with adverse short-term and long-term outcomes in elderly HCC patients undergoing hepatic resection. Our findings suggest that frailty assessment should be incorporated into perioperative and postoperative prognosis evaluation, and particular attention should be given to frail elderly patients undergoing this procedure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tian Yang.
Funding
National Natural Science Foundation of China; Dawn Project Foundation of Shanghai; Shanghai Health Academic Leader Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18